NasdaqGM - Delayed Quote • USD
Marinus Pharmaceuticals, Inc. (MRNS)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:45 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 11 | 11 | 11 | 11 |
Avg. Estimate | -0.66 | -0.6 | -2.19 | -1.29 |
Low Estimate | -0.79 | -0.68 | -2.98 | -2.31 |
High Estimate | -0.61 | -0.48 | -1.7 | -0.65 |
Year Ago EPS | -0.67 | -0.61 | -2.63 | -2.19 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 11 | 11 | 11 | 11 |
Avg. Estimate | 9.12M | 9.59M | 40.84M | 61.88M |
Low Estimate | 7.3M | 7.91M | 33.22M | 41.5M |
High Estimate | 15.26M | 12.1M | 55.3M | 127.7M |
Year Ago Sales | 10.38M | 6.08M | 30.99M | 40.84M |
Sales Growth (year/est) | -12.10% | 57.70% | 31.80% | 51.50% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.72 | -0.72 | -0.66 | -0.62 |
EPS Actual | -0.67 | -0.61 | -0.61 | -0.74 |
Difference | 0.05 | 0.11 | 0.05 | -0.12 |
Surprise % | 6.90% | 15.30% | 7.60% | -19.40% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.66 | -0.6 | -2.19 | -1.29 |
7 Days Ago | -0.66 | -0.6 | -2.19 | -1.29 |
30 Days Ago | -0.63 | -0.58 | -2.37 | -1.89 |
60 Days Ago | -0.58 | -0.56 | -2.27 | -1.63 |
90 Days Ago | -0.58 | -0.56 | -2.26 | -1.64 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 5 | 4 | 7 | 8 |
Up Last 30 Days | 5 | 4 | 7 | 8 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 2 | 4 | 3 | 2 |
Growth Estimates
CURRENCY IN USD | MRNS | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 1.50% | -- | -- | 2.60% |
Next Qtr. | 1.60% | -- | -- | 13.40% |
Current Year | 16.70% | -- | -- | 5.20% |
Next Year | 41.10% | -- | -- | 13.30% |
Next 5 Years (per annum) | 20.00% | -- | -- | 11.11% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | Truist Securities: Buy to Buy | 4/17/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/16/2024 |
Downgrade | Baird: Outperform to Neutral | 4/16/2024 |
Downgrade | RBC Capital: Outperform to Sector Perform | 4/15/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/10/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/26/2024 |
Related Tickers
ABEO Abeona Therapeutics Inc.
3.1900
+0.63%
GLYC GlycoMimetics, Inc.
1.7100
-7.82%
LGVN Longeveron Inc.
1.6700
-2.91%
NKGN NKGen Biotech, Inc.
1.9800
+15.79%
ABVC ABVC BioPharma, Inc.
1.5900
+7.43%
VNDA Vanda Pharmaceuticals Inc.
4.4800
-1.75%
VINC Vincerx Pharma, Inc.
0.8967
-3.58%
PALI Palisade Bio, Inc.
6.23
-1.89%
BPTH Bio-Path Holdings, Inc.
2.6350
+5.40%
EFTR eFFECTOR Therapeutics, Inc.
1.8100
-2.16%